One explanation was that luminal BCs were slowly proliferating tumors that were more amenable to local therapy and benefited from longer endocrine therapy, while HER2-amplified BC and TNBC were rapidly proliferating tumors that were sensitive to NACT (20). The gene discussed is ERBB2; the disease is breast cancer.